Papaverine
ALIMENTARY TRACT AND METABOLISM
Also known as: papaverin, papaverine HCl, papaverine hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Papaverine is a drug catalogued in DrugCentral. DrugCentral lists 20 molecular targets, including PDE10A, Pde10a and PDE3A. Recorded indications include Cerebral ischemia and Peripheral vascular disease.
- Molecular targets: PDE10A, Pde10a, PDE3A and PDE3B (20 listed in DrugCentral).
- Indications: Cerebral ischemia and Peripheral vascular disease.
- ATC code: A03AD01 (Papaverine and derivatives).
- Molecular formula: C20H21NO4; molecular weight 339.39 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Cerebral ischemia
- Peripheral vascular disease
Contraindications (11)
- Angina pectoris
- Cardiac Conduction Delay
- Chronic myocardial ischemia
- Complete atrioventricular block
- Conduction disorder of the heart
- Disease of liver
- Disorder of coronary artery
- Glaucoma
- Low blood pressure
- Myocardial infarction
- Sinus tachycardia
Mechanism & targets
Molecular targets (20)
| Target | Gene | Action | Activity |
|---|---|---|---|
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | PDE10A | unknown | IC50 7.77 |
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Pde10a | unknown | IC50 7.44 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | PDE3A | unknown | Ki 6.55 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | PDE3B | unknown | Ki 6.38 |
| Cyclic nucleotide phosphodiesterase PDE3A | — | unknown | IC50 6.21 |
| Cytochrome P450 2C19 | CYP2C19 | unknown | IC50 6.12 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | PDE4A | unknown | IC50 6.09 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | PDE4D | unknown | IC50 5.85 |
| Cyclic AMP-specific phosphodiesterase SSPDE4A1A | PDE4A | unknown | IC50 5.77 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | PDE2A | unknown | IC50 5.64 |
| Serine hydroxymethyltransferase, mitochondrial | SHMT2 | unknown | IC50 5.57 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 5.14 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | PDE5A | unknown | IC50 5.06 |
| Phosphodiesterase 1 | PDE1A|PDE1B | unknown | IC50 5.06 |
| Phosphodiesterase 1 | PDE1A|PDE1B|PDE1C | unknown | IC50 5.05 |
| Phosphodiesterase 1 | Pde1b|Pde1c|Pde1a | unknown | IC50 4.92 |
| Acetylcholinesterase | ache | unknown | IC50 4.61 |
| Acetylcholinesterase | ACHE | unknown | IC50 4.61 |
| Protein-arginine deiminase type-4 | PADI4 | unknown | IC50 4.41 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | PDE4B | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| — | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A03AD01 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Papaverine and derivatives |
G04BE02 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs used in erectile dysfunction |
G04BE52 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs used in erectile dysfunction |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxicity to various agents | 433.6 |
| Drug abuse | 318.8 |
| Sedation complication | 202.2 |
| Creatinine renal clearance decreased | 201.7 |
| Blood calcium decreased | 168.3 |
| Renal function test abnormal | 160.1 |
| Depressed level of consciousness | 156.9 |
| Drug interaction | 146.5 |
| Orthostatic hypotension | 140.2 |
| Sedation | 132.1 |
| Multiple drug therapy | 130.4 |
| Creatinine renal clearance increased | 129.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Papaverine is on its molecule page.
| Molecular formula | C20H21NO4 |
|---|---|
| Molecular weight | 339.39 g/mol |
| CAS number | 58-74-2 |
| InChIKey | XQYZDYMELSJDRZ-UHFFFAOYSA-N |
| PubChem CID | 4680 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Papaverine used for?
DrugCentral lists the following indications for Papaverine: Cerebral ischemia and Peripheral vascular disease.
How does Papaverine work?
Its molecular targets in DrugCentral include PDE10A, Pde10a, PDE3A and PDE3B.
What is the chemical formula of Papaverine?
Papaverine has the molecular formula C20H21NO4 and a molecular weight of 339.39 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2056 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL19224 — compound record and bioactivity
- PubChem CID 4680 — chemical identifiers
- DrugBank DB01113 — drug record
- FDA UNII DAA13NKG2Q — substance identity
- DailyMed: FDA labels for Papaverine — current prescribing information (label search)
- UniProt Q9Y233 (PDE10A) — target protein
- UniProt Q14432 (PDE3A) — target protein
- UniProt Q13370 (PDE3B) — target protein
- UniProt P33261 (CYP2C19) — target protein
- UniProt P27815 (PDE4A) — target protein
- UniProt Q08499 (PDE4D) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.